RxDoctor Payments Data

Marco Gabbai

Acute Care · Baltimore, MDNPI 1073983482

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 40 payments — averaging $29.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$467
  • Novartis$191
  • AstraZeneca$147
  • Scpharmaceuticals Inc.$87
  • E.r. Squibb & Sons, L.L.C.$78
  • Veloxis Pharmaceuticals, Inc.$59
  • plus $159 from 6 others

What the payments were for

  • Food & beverage$1,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 80th percentile of 502 acute care providers in Maryland.

See all acute care providers in Maryland

Medicare billing

Part B allowed, 2024
$48,299
Medicare patients
315
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban62$82,354
JardianceEmpagliflozin40$53,220
EntrestoSacubitril/Valsartan25$34,713
Repatha SureclickEvolocumab15$23,024
Repatha SyringeEvolocumab16$14,157
Atorvastatin Calcium123$2,047
Metoprolol Succinate89$1,742
Rosuvastatin Calcium49$1,608
Ezetimibe24$1,498
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$1,106
Pravastatin Sodium20$1,017
Carvedilol74$848
ClopidogrelClopidogrel Bisulfate53$841
Isosorbide Mononitrate ErIsosorbide Mononitrate37$819
Labetalol Hcl14$533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$82,35462 claims
Boehringer IngelheimJardiance$467$53,22040 claims
NovartisEntresto$191$34,71325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 502 acute care providers in Maryland.

Other acute care in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →